ATAI Life Sciences’ Initial Public Offering

Dentons and Latham & Watkins advised ATAI Life Sciences on the deal, while Davis Polk advised the underwriters. Clinical-stage biopharmaceutical company ATAI Life Sciences launched its…

This content is for Standard 1 Year members only.
Login Join Now

Surgery Partners’ $800 Million High Yield Senior Notes Offering

SK Capital’s $2.95 Billion Closing of Fund VI

NRDC and BB Kapital’s Acquisition of Galeria

Atem’s Distribuidora de Petroleo’s R$100 Million Debentures Issuance

Inverfal’s Debt Securities Program

Muon Group’s Registration as Acquirer in Colombia

Trianon’s Shares Offering

Lloyds Bank’s £62m Launch of the Community Investment Enterprise Fund

FairCap’s Acquisition of CNH Industrial Sweden

KOKO Networks Limited’s Financing Round

India Vehicle Finance’s Notes Offering

Al-Arafa’s Demerger into Concrete Fashion Group and GTEX

SC Ventures’ $100 Million Joint Venture With SBI Holdings

GreenCorp’s Acquisition of Emad Bakeries

BeyondTrust’s Acquisition of Entitle I.O

Collective Newsroom Private Limited’s Restructuring of India operations of BBC

D3 Bio’s $62 Million Series A Financing Round

Sinopharm Group’s HK$15.6 Billion Privatization Of China TCM

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Hefesto Asesores continues to consolidate its position in the International Private Equity and Venture Capital market, with the formation of Hefesto Global

Paul Hastings Adds Premier Private Equity Buyout Team

The Distinctive Character Of The ‘Vespa’ Is No Longer In Question

Cultural Heritage Sites With Restrictions On Intended Use: The Council of State Acknowledges That This Power Lies In the Hands Of The Ministry Of Culture

The Italian Revenue Agency Qualifies Directors’ Reversible Remuneration For The Purposes Of Double Taxation Agrements.

Labor and Employment Lawyer Sydney Jones Lampard Joins King & Spalding in Washington, D.C.

Paul Hastings Adds Premier Private Equity Buyout Team

BCLP Appoints Trevor Varnes as Chief Financial Officer

ATAI Life Sciences’ Initial Public Offering

Author: Federica Tiefenthaler